{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:24Z","timestamp":1780988004335,"version":"3.54.1"},"reference-count":97,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCLs) present a significant clinical challenge despite recent advances in the development of novel therapeutic agents, guided by a deeper understanding of the pathobiology and the genetic and molecular characteristics underlying this complex and heterogeneous group of aggressive non-Hodgkin lymphomas (NHLs) [...]<\/jats:p>","DOI":"10.3390\/cancers17071134","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:06:35Z","timestamp":1743141995000},"page":"1134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nodal Peripheral T-Cell Lymphoma: Therapeutic Challenges and Future Perspectives"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-2882","authenticated-orcid":false,"given":"Ho Pui Jeff","family":"Lam","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne O.","family":"Arulogun","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Gleeson","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 9RT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"International T-Cell Lymphoma Project (2008). International Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes. J. Clin. Oncol., 26, 4124\u20134130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK\u2212Anaplastic Large-Cell Lymphoma is Clinically and Immunophenotypically Different from Both ALK + ALCL and Peripheral T-Cell Lymphoma, Not Otherwise Specified: Report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bjhh.2015.03.017","article-title":"Primary Nodal Peripheral T-Cell Lymphomas: Diagnosis and Therapeutic Considerations","volume":"37","author":"Lage","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","article-title":"Analysis of Peripheral T-Cell Lymphoma Diagnostic Workup in the United States","volume":"17","author":"Hsi","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2023021786","article-title":"A Practical Approach to the Modern Diagnosis and Classification of T-and NK-Cell Lymphomas","volume":"144","author":"Gaulard","year":"2024","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-World Data on Prognostic Factors and Treatment in Peripheral T-Cell Lymphomas: A Study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Weiss, J., Reneau, J., and Wilcox, R.A. (2023). PTCL, NOS: An Update on Classification, Risk-Stratification, and Treatment. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1101441"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdq359","article-title":"Comparison of Four Prognostic Scores in Peripheral T-Cell Lymphoma","volume":"22","author":"Cardesa","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-024-01560-7","article-title":"Novel Clinical Risk Stratification and Treatment Strategies in Relapsed\/Refractory Peripheral T-Cell Lymphoma","volume":"17","author":"Chang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-Term Outcome of Adults with Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d\u2019\u00c9tude Des Lymphomes de l\u2019Adulte Trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in Understanding of Angioimmunoblastic T-Cell Lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/bloodadvances.2020001636","article-title":"Clonal Hematopoiesis in Angioimmunoblastic T-Cell Lymphoma with Divergent Evolution to Myeloid Neoplasms","volume":"4","author":"Lewis","year":"2020","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hathuc, V., and Kreisel, F. (2022). Genetic Landscape of Peripheral T-Cell Lymphoma. Life, 12.","DOI":"10.3390\/life12030410"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The Biology and Management of Systemic Anaplastic Large Cell Lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 Expression in Peripheral T-Cell Lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","article-title":"Discovery of Recurrent t(6;7)(P25.3;Q32.3) Translocations in ALK-Negative Anaplastic Large Cell Lymphomas by Massively Parallel Genomic Sequencing","volume":"117","author":"Feldman","year":"2011","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-Negative Anaplastic Large Cell Lymphoma Is a Genetically Heterogeneous Disease with Widely Disparate Clinical Outcomes","volume":"124","author":"Jaffe","year":"2014","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2022.281222","article-title":"DUSP22 Rearrangement is Associated with a Distinctive Immunophenotype but Not Outcome in Patients with Systemic ALK-Negative Anaplastic Large Cell Lymphoma","volume":"108","author":"Qiu","year":"2023","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of High-Risk DUSP22-Rearranged ALK-Negative Anaplastic Large Cell Lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3324\/haematol.2022.281442","article-title":"ALK-Negative Anaplastic Large Cell Lymphoma with DUSP22 Rearrangement Has Distinctive Disease Characteristics with Better Progression-Free Survival: A LYSA Study","volume":"108","author":"Sibon","year":"2023","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.exphem.2021.12.191","article-title":"Recent Advances in T-Cell Lymphoid Neoplasms","volume":"106","author":"Bigas","year":"2022","journal-title":"Exp. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.3324\/haematol.2023.282716","article-title":"Pathobiology of Nodal Peripheral T-Cell Lymphomas: Current Understanding and Future Directions","volume":"108","author":"Bisig","year":"2023","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin\u2019s Lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study","volume":"27","author":"Reimer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in Previously Untreated Patients with Peripheral T-Cell Lymphoma (CHEMO-T): A Phase 2, Multicentre, Randomised, Open-Label Trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 Trial of Combined Cisplatin, Etoposide, Gemcitabine, and Methylprednisolone (PEGS) in Peripheral T-Cell Non-Hodgkin Lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-Reinforced-ABVD (VIP-RABVD) is Not Superior to CHOP\/21 in Newly Diagnosed Peripheral T Cell Lymphoma. Results of the Randomized Phase III Trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: An Analysis of Patients with T-Cell Lymphoma Treated in Studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/blood-2018-99-110429","article-title":"Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant","volume":"132","author":"Silva","year":"2018","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in Elderly Patients with Peripheral T-Cell Lymphoma: The DSHNHL2006-1B\/ACT-2 Trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Oncology Group Study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative Analysis of a Phase 2 Trial Combining Lenalidomide with CHOP in Angioimmunoblastic T-Cell Lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-Year Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-Year Results of a Randomized, Phase III Study of Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab Vedotin plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone Followed by Brentuximab Vedotin Consolidation in CD30-Positive Peripheral T-Cell Lymphomas: A Multicentre, Single-Arm, Phase 2 Study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1200\/JCO.2024.42.16_suppl.7069","article-title":"Frontline Brentuximab Vedotin and CHP (A + CHP) in Patients (Pts) with Peripheral T-Cell Lymphoma with Less than 10% CD30 Expression: Results from the Phase 2 SGN35-032 Study","volume":"42","author":"Iyer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of Stem Cell Transplant in CD30-Positive PTCL Following Frontline Brentuximab Vedotin+ CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"Relander","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-Line Therapy of Peripheral T-Cell Lymphoma: Extension and Long-Term Follow-up of a Study Investigating the Role of Autologous Stem Cell Transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma for Patients in Response after Induction: An Analysis of Patients from LYSA Centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The Role of Autologous Stem Cell Transplantation in Patients with Nodal Peripheral T-cell Lymphomas in First Complete Remission: Report from COMPLETE, a Prospective, Multicenter Cohort Study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous Stem-Cell Transplantation as Consolidation of First-Line Chemotherapy in Patients with Peripheral T-Cell Lymphoma: A Multicenter GELTAMO\/FIL Study","volume":"107","author":"Bellei","year":"2022","journal-title":"Haematologica"},{"key":"ref_49","first-page":"2646","article-title":"A Randomized Phase 3 Trial of Auto vs. Allo Transplantation as Part of First-Line Therapy in Poor-Risk Peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma after Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a Multicenter, Open-Label, Pivotal Phase II Study of Chidamide in Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2022-156789","article-title":"Oral Azacytidine in Patients with Relapsed\/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study","volume":"140","author":"Dupuis","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2023-179304","article-title":"Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2024-203577","article-title":"Duvelisib in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial","volume":"144","author":"Zinzani","year":"2024","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1158\/1078-0432.CCR-24-1194","article-title":"A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and\/or Refractory Peripheral T-Cell Lymphoma","volume":"30","author":"Jin","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the Pivotal PROPEL Study","volume":"29","author":"Pro","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A Phase 2 Biomarker-Driven Study of Ruxolitinib Demonstrates Effectiveness of JAK\/STAT Targeting in T-Cell Lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a Selective JAK1 Tyrosine-Kinase Inhibitor, in Patients with Refractory or Relapsed Peripheral T-Cell Lymphoma (JACKPOT8 Part B): A Single-Arm, Multinational, Phase 2 Study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A Phase 2, Multicentre, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid\u00ae) in Subjects with Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma: The EXPECT Trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final Report of a Phase 2 Clinical Trial of Lenalidomide Monotherapy for Patients with T-Cell Lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-Cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2024-205617","article-title":"Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory\/Advanced Cutaneous T Cell Lymphoma","volume":"144","author":"Querfeld","year":"2024","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in Combination with Standard Cyclophosphamide, Doxorubicin, Vincristine and Prednisone as First-Line Treatment for Patients with Newly Diagnosed Peripheral T-Cell Lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T Follicular Helper Phenotype Predicts Response to Histone Deacetylase Inhibitors in Relapsed\/Refractory Peripheral T-Cell Lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/bloodadvances.2023011095","article-title":"Pralatrexate Injection Combined with CHOP for Treatment of PTCL: Results from the Fol-CHOP Dose-Finding Phase 1 Trial","volume":"8","author":"Iyer","year":"2024","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating with Pralatrexate (P) as Front Line Therapy for Patients with Peripheral T-Cell Lymphoma (PTCL): Final Results from the T-Cell Consortium Trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/j.clml.2022.07.009","article-title":"Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-Cell Lymphoma","volume":"22","author":"Yoon","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral Azacitidine Compared with Standard Therapy in Patients with Relapsed or Refractory Follicular Helper T-Cell Lymphoma (ORACLE): An Open-Label Randomised, Phase 3 Study","volume":"11","author":"Dupuis","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136023","article-title":"Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP as Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)","volume":"136","author":"Ruan","year":"2020","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2024-206606","article-title":"Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)","volume":"144","author":"Ruan","year":"2024","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1158\/1078-0432.CCR-20-4224","article-title":"Activity of Crizotinib in Patients with ALK-Aberrant Relapsed\/Refractory Neuroblastoma: A Children\u2019s Oncology Group Study (ADVL0912)","volume":"27","author":"Foster","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1200\/JCO.22.00272","article-title":"Crizotinib in Combination with Chemotherapy for Pediatric Patients with ALK1 Anaplastic Large-Cell Lymphoma: The Results of Children\u2019s Oncology Group Trial ANHL12P1","volume":"41","author":"Lowe","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus Chemotherapy in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer Previously given Chemotherapy and Crizotinib (ASCEND-5): A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in Patients with Advanced ALK-Positive Non\u2013Small Cell Lung Cancer: 5-Year Outcomes from the Phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: An Open-Label Phase II Trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood-2014-12-617779","article-title":"Ceritinib in Patients with Advanced Anaplastic Lymphoma Kinase\u2013Rearranged Anaplastic Large-Cell Lymphoma","volume":"126","author":"Richly","year":"2015","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2021-148939","article-title":"Duvelisib in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis","volume":"138","author":"Brammer","year":"2021","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"TPS7593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7593","article-title":"Alliance A059102: A Randomized Phase II U.S. Intergroup Study of CHO(E)P versus CC-486-CHO(E)P versus Duvelisib-CHO(E)P in Previously Untreated, CD30-Negative, Peripheral T-Cell Lymphomas","volume":"40","author":"Geyer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The Combination of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, and Romidepsin is Highly Active in Relapsed\/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1182\/blood-2024-204392","article-title":"Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphomas","volume":"144","author":"Ford","year":"2024","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","article-title":"Multicenter Phase 2 Study of Romidepsin plus Lenalidomide for Previously Untreated Peripheral T-Cell Lymphoma","volume":"7","author":"Ruan","year":"2023","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A Phase 1 Study of Romidepsin and Pralatrexate Reveals Marked Activity in Relapsed and Refractory T-Cell Lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1016\/S2152-2650(23)01392-7","article-title":"TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis","volume":"23","author":"Iyer","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined Oral 5-Azacytidine and Romidepsin Are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood-2024-199196","article-title":"Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed\/Refractory T-Cell Lymphoma","volume":"144","author":"Gordon","year":"2024","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2024-205173","article-title":"A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma","volume":"144","author":"Saeed","year":"2024","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2024-206462","article-title":"Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1182\/blood-2024-201294","article-title":"Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas","volume":"144","author":"Reneau","year":"2024","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1182\/blood-2024-206302","article-title":"The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2024-200882","article-title":"The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study","volume":"144","author":"Xia","year":"2024","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma: Primary Analysis of the Phase 3 TRANSFORM Study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"20406207221143025","DOI":"10.1177\/20406207221143025","article-title":"Current State of CAR-T Therapy for T-Cell Malignancies","volume":"13","author":"Luo","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1182\/blood-2022-165971","article-title":"First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed\/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma","volume":"140","author":"Cwynarski","year":"2022","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:04:13Z","timestamp":1760029453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":97,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071134"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071134","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}